←
Fractyl Health786 posts
Fractyl Health avatar

Fractyl Health

@FractylHealth

We are innovators working to break the pattern in the treatment of obesity.

◷ Joined August 2014▧ 237 Photos and videos
Harith Rajagopalan avatar
⟳ Fractyl Health retweeted
Harith Rajagopalan@Harithr·May 1

Proud to see coverage of our REMAIN-1 interim midpoint data in @Reuters: In the study, Revita DMR-treated patients (highest-dose group) maintained >80% of weight loss with ~7 lb regain at 6 months after stopping GLP-1s like tirzepatide, vs. ~ double in sham. Revita is Investigational Use Only in the US. Full pivotal cohort data and potential regulatory submission planned later 2026. reuters.com/business/healthc…

Fractyl Health avatar
Fractyl Health@FractylHealth·17 Dec 2025

At Fractyl Health, our team is driven by a shared mission: to transform care for people living with obesity and type 2 diabetes through durable, impactful innovation. This month, we’re proud to spotlight Lindsay Dee, Legal Operations Manager & Senior Paralegal, whose commitment to advancing meaningful change reflects the heart of our work. “I hope people living with obesity can access treatments that really work; ones that go beyond managing symptoms to help them feel healthy and confident again. I believe in a future where obesity care supports lasting wellbeing, even amid busy lives.” We’re grateful for Lindsay and for every member of our team who brings this purpose to life every day. #FractylForward #TeamFractyl

Post attachment
Fractyl Health avatar
Fractyl Health@FractylHealth·2 Dec 2025

We are pleased to share new 6-month open-label data from the REVEAL-1 Cohort, marking another important milestone in our pursuit of innovative, durable solutions for people living with #metabolicdisease. The findings reinforce an encouraging trend: Revita® may help individuals maintain their weight after discontinuing GLP-1 drugs, underscoring the potential for longer-lasting metabolic control in #obesity. Thank you to our participants, investigators, partners, and the Fractyl team for advancing this important work. Read more about the data: ir.fractyl.com/news-releases… *Revita® is for Investigational Use Only in the U.S. under Federal law* #FractylForward

Post attachment
Fractyl Health avatar
Fractyl Health@FractylHealth·26 Sep 2025

#News for #Investors and #Media: At 3 months, Revita® patients lost an additional 2.5% of total body weight after stopping GLP-1 therapy, while sham patients regained 10% (p=0.014). These randomized, blinded data support the potential for Revita to be the first therapy for post-GLP-1 weight maintenance. Watch the results below and read the full press release: ir.fractyl.com/news-releases… #ObesityCare #WeightLoss #GLP1 #Revita *Revita® is for Investigational Use Only in the U.S. under Federal law*

0:26
Fractyl Health avatar
Fractyl Health@FractylHealth·1 Apr 2025

Fractyl Health (NASDAQ: $GUTS) today announced positive early data from the REVEAL-1 cohort of the ongoing REMAIN-1 pivotal study. Results show that the Revita® procedure – designed to address a root cause of obesity – has the potential to prevent weight regain after GLP-1 drug discontinuation. With GLP-1 adoption surging and discontinuation rates rising, these data point to a significant, under-addressed commercial opportunity: providing a scalable, non-pharmacologic solution to sustain weight loss without chronic drug use. Learn more: bit.ly/4hP1Mih #FractylForward #Obesity #ClinicalTrial #DataAnnouncement *Revita is for Investigational Use Only in the US under Federal law*

Post attachment
Fractyl Health avatar
Fractyl Health@FractylHealth·14 Mar 2025

Extra-wide spectator seating. Bariatric ambulances. Oversized coffins. With more than half of the world’s population expected to have obesity by 2050, this @guardian article paints a sobering picture of how stadiums, hospitals, airlines and other industries are adapting to the global obesity emergency. theguardian.com/society/2025…… But what if we could change this trajectory by reversing obesity rather than accommodating it? We can imagine a world where all this is possible. The progress made with GLP-1 drugs has allowed one massive step in that direction. Our work at Fractyl Health aims to solve the problem by allowing people to live their lives at a lower weight – freely. #Obesity #HealthInnovation #AskAQuestionDay #FractylForward

Fractyl Health avatar
Fractyl Health@FractylHealth·8 Mar 2025

Did you know that #obesity disproportionately impacts women? Nearly 42% of adult women in the U.S. live with obesity, placing them at increased risk for conditions like #heartdisease, #diabetes, and certain #cancers. Raising awareness and advancing solutions are essential steps towards improving women’s health outcomes. Women are the foundation of families and communities, often juggling multiple roles as professionals, caregivers and leaders. Their health and well-being are crucial – not just for themselves, but for society overall. When women thrive, communities flourish. Research, advocacy, and access to effective treatments all play a role in addressing this public health crisis. At Fractyl, we’re breaking the pattern of obesity treatment by addressing the root cause of this disease, to help ensure that women have the support they need to take charge of their health. #FractylForward #IWD2025 #WomensHistoryMonth #ObesityAwareness #WomenInHealth

Fractyl Health avatar
Fractyl Health@FractylHealth·13 Jan 2025

BREAKING: We're excited to announce promising initial clinical results from the first patient in the REVEAL-1 open-label cohort of our REMAIN-1 study. We're seeing positive results after one month of #GLP1 drug discontinuation alongside the Revita procedure, in line with trends observed in prior Revita clinical studies. Additionally, we're reporting significant progress in our REMAIN-1 pivotal study, evaluating weight maintenance after GLP-1 discontinuation. With more than 100 patients enrolled across the first 8 clinical study sites in less than 4 months since first site activation, this milestone reflects strong engagement from both #patients and #physicians. Read more about today's announcements: bit.ly/40u8Hbl $GUTS #FractylForward #ObesityData #Obesity

Fractyl Health avatar
Fractyl Health@FractylHealth·27 Dec 2024

We’ve had a banner year at Fractyl Health. From going public, to presenting compelling data across the country to investors and scientists and receiving a Breakthrough Device designation from the FDA - we're celebrating our successes and looking #FractylForward to a big 2025 full of critical catalysts. We're deeply appreciative of our employees, our Board, our investors, our physician partners, and most importantly our patients for propelling us forward each day and making significant strides in the fight against #obesity and #T2D. We look forward to continuing this momentum in 2025!

Post attachment